We are live on ! Find out more
ENGN icon

enGene Therapeutics
ENGN

57 hedge funds and large institutions have $530M invested in enGene Therapeutics in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 6

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

90% more capital invested

Capital invested by funds: $279M → $530M (+$251M)

54% more funds holding

Funds holding: 37 → 57 (+20)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

7.82% more ownership

Funds ownership: 79.81% → 87.63% (+7.8%)

Holders
57
Holders Change
+20
Holders Change %
+54.05%
% of All Funds
0.69%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
26
Increased
17
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$30.2M
2
SL
Siren LLC
Connecticut
+$26.7M
3
DTC
Deep Track Capital
Connecticut
+$17.1M
4
NI
Nextech Invest
Switzerland
+$17M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$15.2M

Top Sellers

Rank Fund Capital Flow
1
KCM
Kynam Capital Management
New Jersey
-$28.1M
2
FLSM
Frazier Life Sciences Management
California
-$7.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.83M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.18M
5
Bank of America
Bank of America
North Carolina
-$4.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
ADAR1 Capital Management
Texas
$2.74M +$2.43M +303,686 New
MIM
27
Monashee Investment Management
Massachusetts
$2.66M +$2.36M +295,000 New
WP
28
Woodline Partners
California
$2.26M +$2M +250,000 New
EC
29
Elmind Capital
New York
$1.9M +$1.68M +210,000 New
DCM
30
DAFNA Capital Management
California
$1.48M +$1.31M +163,645 New
Two Sigma Investments
31
Two Sigma Investments
New York
$1.46M +$1.29M +161,512 New
Goldman Sachs
32
Goldman Sachs
New York
$1.34M +$2.3K +287 +0.2%
KCM
33
Kennedy Capital Management
Missouri
$693K +$615K +76,765 New
HF
34
HRT Financial
New York
$581K +$516K +64,380 New
Jane Street
35
Jane Street
New York
$510K +$452K +56,454 New
QC
36
Quadrature Capital
United Kingdom
$439K +$389K +48,583 New
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$324K +$287K +35,877 New
VIA
38
Virtus Investment Advisers
Connecticut
$284K +$252K +31,445 New
Northern Trust
39
Northern Trust
Illinois
$272K -$1.68K -210 -0.7%
Geode Capital Management
40
Geode Capital Management
Massachusetts
$262K – – –
Citadel Advisors
41
Citadel Advisors
Florida
$229K -$264K -32,987 -57%
PFCS
42
Pale Fire Capital SE
Czech Republic
$217K +$54.1K +6,750 +39%
American Century Companies
43
American Century Companies
Missouri
$217K +$192K +23,980 New
XT
44
XTX Topco
Cayman Islands
$216K +$192K +23,922 New
Renaissance Technologies
45
Renaissance Technologies
New York
$188K +$167K +20,782 New
Raymond James Financial
46
Raymond James Financial
Florida
$180K +$79.8K +9,960 +100%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$156K +$139K +17,300 New
SSA
48
Schonfeld Strategic Advisors
New York
$150K -$67.5K -8,425 -34%
JF
49
Jump Financial
Illinois
$121K +$107K +13,400 New
Wells Fargo
50
Wells Fargo
California
$101K -$53.6K -6,693 -37%
1
2
3

ENGN Hedge Fund Activity: Q4 2025 in Review

57 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q4 2025, worth a combined $530M — up 90% from $279M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ENGN positions and 6 closed out — a net gain of 20 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $30.2M. The largest seller was Kynam Capital Management, cutting an estimated $28.1M.

  • 57 institutional investors held enGene Therapeutics (ENGN) as of Q4 2025, up from 37 in Q3 2025.
  • Funds reported $530M of enGene Therapeutics stock for Q4 2025, up 90% quarter-over-quarter.
  • 26 funds opened new enGene Therapeutics positions in Q4 2025 and 6 closed out, a net change of +20 holders.
  • The largest enGene Therapeutics buyer in Q4 2025 was Perceptive Advisors, an estimated $30.2M added.
  • The largest enGene Therapeutics seller in Q4 2025 was Kynam Capital Management, an estimated $28.1M sold.

Based on aggregated 13F filings for Q4 2025.